Engineered immune cells take on Hard-to-Treat lymphoma
NCT ID NCT07162012
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 25 times
Summary
This early-phase trial tests a personalized cell therapy for people with a specific type of lymphoma linked to the Epstein-Barr virus (EBV). The treatment uses the patient's own immune cells, modified to recognize and attack EBV-infected cancer cells. The study aims to find a safe dose and check for early signs of effectiveness in 24 adults whose lymphoma has returned or not responded to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.